These data describe a non-canonical Wnt/PCP pathway overexpressing VANGL2 in aggressive breast cancer and identify p62/SQSTM1 as an important player in VANGL2–JNK signalling. This evidence concerns the gene SQSTM1 and breast carcinoma.